RT Journal Article
SR Electronic
T1 Metabolomic and lipidomic signatures in autosomal dominant and late-onset Alzheimer disease brains
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.11.04.21265941
DO 10.1101/2021.11.04.21265941
A1 Novotny, Brenna C
A1 Fernandez, Maria Victoria
A1 Wang, Ciyang
A1 Budde, John P
A1 Bergmann, Kristy
A1 Eteleeb, Abdallah
A1 Bradley, Joseph
A1 Webster, Carol
A1 Ebl, Curtis
A1 Norton, Joanne
A1 Gentsch, Jen
A1 Dube, Umber
A1 Wang, Fengxian
A1 Morris, John C
A1 Bateman, Randall J
A1 Perrin, Richard J
A1 McDade, Eric
A1 Xiong, Chengjie
A1 Chhatwal, Jasmeer
A1 Dominantly Inherited Alzheimer Network Study Group
A1 Alzheimer’s Disease Neuroimaging Initiative
A1 Alzheimer’s Disease Metabolomics Consortium
A1 Goate, Alison
A1 Farlow, Martin
A1 Schofield, Peter
A1 Chui, Helena
A1 Karch, Celeste M
A1 Benitez, Bruno A
A1 Cruchaga, Carlos
A1 Harari, Oscar
YR 2021
UL http://medrxiv.org/content/early/2021/11/30/2021.11.04.21265941.abstract
AB The identification of multiple genetic risk factors for Alzheimer Disease (AD) provides evidence to support that many pathways contribute to AD onset and progression. However, the metabolomic and lipidomic profiles in carriers of distinct genetic risk factors are not fully understood. The metabolome can provide a direct image of dysregulated pathways in the brain, including information on treatment targets. In this study, we interrogate the metabolomic and lipidomic signatures in the AD brain, including carriers of pathogenic variants in APP, PSEN1, and PSEN2 (autosomal dominant AD; ADAD), APOE ε4 and TREM2 risk variant carriers, and non-carrier sporadic AD (sAD). We generated metabolomic and lipidomic data from parietal cortical tissue from 366 participants with AD pathology and 26 cognitively unimpaired controls using the Metabolon global metabolomics platform. We identified 133 metabolites associated with disease status (FDR q-value<0.05). In sAD brains these include tryptophan betaine (b=-0.57) and N-acetylputrescine (b=-0.14). Metabolites associated with sAD and ADAD include ergothioneine (b=-0.21 and -0.26 respectively) and serotonin (b=-0.34 and -0.58, respectively). TREM2 and ADAD showed association with α-tocopherol (b=-0.12 and -0.12) and CDP-ethanolamine (b=-0.13 and -0.10). β-citrylglutamate levels are associated with sAD, ADAD, and TREM2 compared to controls (b=-0.15; -0.22; and -0.29, respectively). Additionally, we identified a signature of 16 metabolites that is significantly altered between genetic groups (sAD vs. control p = 1.05×10-7, ADAD vs. sAD p = 3.21×10-5) and is associated with Braak tau stage and disease duration. These data are available to the scientific community through a public web browser (http://ngi.pub/Metabolomics). Our findings were replicated in an independent cohort of 327 individuals.Competing Interest StatementCC receives research support from: Biogen, EISAI, Alector and Parabon. The funders of the study had no role in the collection, analysis, or interpretation of data; in the writing of the report; or in the decision to submit the paper for publication. CC is a member of the advisory board of Vivid genetics, Halia Therapeutics and ADx Healthcare.Funding StatementThis work was possible thanks to the following governmental grants from the National institute of Health: NIA R01AG057777, RO1AG057777-02S1, K99AG061281, P30AG066444, P01AGO26276, NINDS R01NS118146 (BAB), R01AG044546 (CC), P01AG003991 (CC, JCM), RF1AG053303 (CC), RF1AG058501 (CC), U01AG058922 (CC), and the Chan Zuckerberg Initiative (CZI). O.H. is an Archer Foundation Research Scientist. This work was supported by access to equipment made possible by the Hope Center for Neurological Disorders, the NeuroGenomics and Informatics Center (NGI: https://neurogenomics.wustl.edu/) and the Departments of Neurology and Psychiatry at Washington University School of Medicine. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:IRB of Washington University School of Medicine in St. Louis gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesMetabolomics data from the Knight ADRC donors generated for this study are available at the NIAGADS and can be accessed at https://www.niagads.org/knight-adrc-collection. Data generated from the DIAN cohort can be requested at https://dian.wustl.edu/our-research/for-investigators/diantu-investigator-resources/dian-tu-biospecimen-request-form/. We have accessed data from the ADNI (https://adni.loni.usc.edu, accessed 18 December, 2020), and ROSMAP (https://synapse.org/#!Synapse:syn26007829, accessed 18 December, 2020 and https://synapse.org/#!Synapse:syn26007830, accessed 30 July, 2021). Additional phenotypic data for the ROSMAP studies is available through the Rush AD Center Resource Sharing Hub (https://www.radc.rush.edu). https://www.niagads.org/knight-adrc-collection https://adni.loni.usc.edu https://synapse.org/#!Synapse:syn26007829 https://synapse.org/#!Synapse:syn26007830 https://www.radc.rush.edu